24/7 Market News Snapshot 14 May, 2025 – Cingulate Inc. Common Stock (NASDAQ:CING)

May 14, 2025

DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (NASDAQ:CING) are discussed in this article.
Cingulate Inc. (NASDAQ:CING) is experiencing notable trading activity, with shares opening at $3.95 and currently priced at $4.315, marking a substantial increase of approximately 10.36% from the prior close of $3.91. The heightened trading volume of 519.08K indicates a surge in investor interest, suggesting a robust bullish trend. The stock’s movement above previous resistance levels could attract additional buying pressure, and maintaining a price above $4.00 may further solidify this upward trajectory. Market participants are encouraged to monitor key support levels and volume changes to evaluate potential price fluctuations in the upcoming sessions.

In addition to its positive market performance, Cingulate has announced crucial pre-New Drug Application (NDA) feedback from the U.S. Food and Drug Administration (FDA) concerning its lead product, CTx-1301 (dexmethylphenidate). This promising therapeutic candidate is aimed at addressing Attention Deficit/Hyperactivity Disorder (ADHD) and is on schedule for NDA submission this summer. Cingulate’s Chairman and CEO, Shane J. Schaffer, expressed optimism about the constructive feedback received from the FDA, emphasizing that the insights provided align with the company’s submission timeline.

CTx-1301 aims to fill a significant gap in ADHD treatment by offering a first-of-its-kind once-daily stimulant medication with all-day efficacy. Utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™) technology, the drug delivers three distinct releases of medication throughout the day, thus optimizing treatment outcomes for patients. Given that over 20 million individuals in the U.S. are diagnosed with ADHD, many of whom remain inadequately treated, the demand for effective and innovative solutions is pressing.

Cingulate intends to utilize its PTR technology to expand its clinical pipeline and pursue additional therapeutic avenues beyond ADHD. This strategic direction underscores the company’s dedication to enhancing patient care through advanced drug delivery methods, while also positioning it to potentially transform treatment paradigms in the future.

Related news for (CING)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.